CREST, a Cas13-Based, Rugged, Equitable, Scalable Testing (CREST) for SARS-CoV-2 Detection in Patient Samples

Area of Science:

• Molecular Biology
• Infectious Diseases
• Biotechnology

Background:

• The COVID-19 pandemic necessitates widespread and accurate SARS-CoV-2 detection for effective control measures.
• Current diagnostic methods require improvement in terms of accessibility, cost, and scalability for global surveillance.

Purpose of the Study:

• To develop and characterize a novel CRISPR-Cas13-based assay for sensitive and specific SARS-CoV-2 detection.
• To present CREST (Cas13-based, rugged, equitable, scalable testing) as a viable alternative for molecular diagnostics.

Main Methods:

• Utilized the CRISPR-Cas13 system for targeted detection of SARS-CoV-2 genetic material.
• Developed protocols for LwaCas13a purification and in vitro transcription of synthetic targets.
• Validated the assay using real-time PCR and fluorescence detection systems.

Main Results:

• The CREST assay demonstrated high specificity and sensitivity for SARS-CoV-2 detection.
• The method proved to be highly accessible and scalable for widespread application.
• CREST offers a dependable and low-cost alternative for SARS-CoV-2 surveillance.

Conclusions:

• CREST is a robust and equitable diagnostic tool for SARS-CoV-2 detection.
• The CRISPR-Cas13-based approach provides a promising solution for global pandemic preparedness and response.
• This technology can significantly aid in continuous and widespread testing efforts.